Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma

Area of Science:

• Oncology
• Translational Research
• Renal Cell Carcinoma

Background:

• Metastatic clear cell renal cell carcinoma (ccRCC) has seen significant therapeutic advances with targeted therapies.
• Metastatic non-clear cell renal cell carcinoma (nccRCC) management has shown limited improvement.
• nccRCC comprises diverse subtypes (e.g., papillary, chromophobe, sarcomatoid) with distinct biology.

Purpose of the Study:

• To highlight the need for subtype-specific treatment strategies in nccRCC.
• To emphasize the limitations of current ccRCC-focused therapies when applied to nccRCC.
• To advocate for biologically relevant therapies tailored to individual nccRCC histologies.

Main Methods:

• Review of current treatment landscapes for ccRCC and nccRCC.
• Analysis of prospective studies aggregating nccRCC histologies.
• Introduction of SWOG 1500 as an example of histology-specific research in papillary RCC.

Main Results:

• Current treatment strategies for ccRCC, such as VEGF- and mTOR-directed therapies, are often inadequately studied in diverse nccRCC subtypes.
• Aggregating nccRCC histologies in clinical trials overlooks crucial biological differences.
• The SWOG 1500 study exemplifies a move towards targeted therapies (VEGF-inhibitor vs. MET-directed) for specific nccRCC subtypes like papillary RCC.

Conclusions:

• Appreciating the biologic diversity of nccRCC is critical for improving patient outcomes.
• Future research must focus on individual nccRCC histologies and employ biologically tailored therapies.
• Without this approach, outcomes for nccRCC are likely to remain poor.